Ignite Creation Date:
2025-12-25 @ 4:28 AM
Ignite Modification Date:
2026-03-03 @ 12:44 AM
Study NCT ID:
NCT03012620
Status:
COMPLETED
Last Update Posted:
2024-02-28
First Post:
2017-01-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
Sponsor:
UNICANCER
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
UC-0105/1612
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None